[Value of ipratropium (Atrovent) in the treatment of chronic obstructive lung diseases in myasthenic patients treated with anticholinesterase agents. Apropos of a case].
We report a case of myasthenia gravis occurring in a 70-year old patient with old chronic bronchitis. Anticholinesterase therapy led to an increase in respiratory symptoms, but relief was obtained with inhaled ipratropium. The activity of this drug was confirmed by spirography. This clinical finding is compared with similar data found in the literature.
Robinet
G
G
Service de Pneumologie et Oncologie thoracique, CHR Morvan, Brest.
Leroyer
C
C
Andre
J
J
Dewitte
J D
JD
Clavier
J
J
D000368:Aged; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001980:Bronchi / Q000187:drug effects; D001986:Bronchial Spasm / Q000139:chemically induced; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009241:Ipratropium / Q000494:pharmacology / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy*; D012129:Respiratory Function Tests
D001286:Atropine Derivatives; D002800:Cholinesterase Inhibitors; D009241:Ipratropium
Intérêt de l'ipratropium (Atrovent*) dans le traitement d'une BPCO chez les sujets myasthéniques recevant des anticholinestérasiques.